Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

510 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units.
Montravers P, Perrigault PF, Timsit JF, Mira JP, Lortholary O, Leroy O, Gangneux JP, Guillemot D, Bensoussan C, Bailly S, Azoulay E, Constantin JM, Dupont H; AmarCAND2 Study Group. Montravers P, et al. Among authors: leroy o. Clin Microbiol Infect. 2017 Feb;23(2):117.e1-117.e8. doi: 10.1016/j.cmi.2016.10.001. Epub 2016 Oct 13. Clin Microbiol Infect. 2017. PMID: 27746395 Free article.
Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.
Bailly S, Leroy O, Montravers P, Constantin JM, Dupont H, Guillemot D, Lortholary O, Mira JP, Perrigault PF, Gangneux JP, Azoulay E, Timsit JF. Bailly S, et al. Among authors: leroy o. Intensive Care Med. 2015 Nov;41(11):1931-40. doi: 10.1007/s00134-015-4053-1. Epub 2015 Sep 14. Intensive Care Med. 2015. PMID: 26370688
Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study.
Leroy O, Bailly S, Gangneux JP, Mira JP, Devos P, Dupont H, Montravers P, Perrigault PF, Constantin JM, Guillemot D, Azoulay E, Lortholary O, Bensoussan C, Timsit JF; AmarCAND2 study group. Leroy O, et al. Ann Intensive Care. 2016 Dec;6(1):2. doi: 10.1186/s13613-015-0103-7. Epub 2016 Jan 8. Ann Intensive Care. 2016. PMID: 26743881 Free PMC article.
Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: A post-hoc causal inference model using the AmarCAND2 study.
Bailly S, Leroy O, Azoulay E, Montravers P, Constantin JM, Dupont H, Guillemot D, Lortholary O, Mira JP, Perrigault PF, Gangneux JP, Timsit JF; AmarCAND2 Study Group. Bailly S, et al. Among authors: leroy o. J Infect. 2017 Apr;74(4):408-417. doi: 10.1016/j.jinf.2016.12.016. Epub 2017 Jan 16. J Infect. 2017. PMID: 28104387 Free article.
Clinical Impact of Antifungal Susceptibility, Biofilm Formation and Mannoside Expression of Candida Yeasts on the Outcome of Invasive Candidiasis in ICU: An Ancillary Study on the Prospective AmarCAND2 Cohort.
Gangneux JP, Cornet M, Bailly S, Fradin C, Féger C, Timsit JF, Leroy O, Sendid B, Bougnoux ME. Gangneux JP, et al. Among authors: leroy o. Front Microbiol. 2018 Dec 11;9:2907. doi: 10.3389/fmicb.2018.02907. eCollection 2018. Front Microbiol. 2018. PMID: 30619103 Free PMC article.
510 results